Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0QKIXN |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | 19G4 |
|||||
| Organization | West China Hospital; West China Medical School; Sichuan University; State Key Laboratory of Biotherapy. |
|||||
| Synonyms |
19G4
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Murine lgG |
|||||
| Antigen Name | Solute carrier family 3 member 2 (SLC3A2) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
38703658 19G4-MMAE [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
2.028۪.4680 nM
|
Positive SLCA2 expression (SLCA2+++/++) | ||
| Method Description |
The MTT assay was performed to determin the in vitro efficacy of the 19G4-MMAE ADC. Cells were seeded in 96-well plates at a density of 5000 cells/well for SCC15, NPC/HK1, FADU, C666-1 at 37 °C and 5% CO2 overnight. Dilutions of PBS, 19G4, IgG-MMAE, and 19G4-MMAE solutions were added to cells for 72 h incubation at 37 °C. Cell viability were evaluated in triplicate by MTT assay. The IC50 was determined using Graphpad Prism version 9 (GraphPad Software, Inc.).
Click to Show/Hide
|
||||
| In Vitro Model | Squamous cell carcinoma of the oral tongue, Tongue squamous cell carcinoma | SCC15 cells | CVCL_1681 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
205.1 nM
|
Positive SLCA2 expression (SLCA2+++/++) | ||
| Method Description |
The MTT assay was performed to determin the in vitro efficacy of the 19G4-MMAE ADC. Cells were seeded in 96-well plates at a density of 5000 cells/well for SCC15, NPC/HK1, FADU, C666-1 at 37 °C and 5% CO2 overnight. Dilutions of PBS, 19G4, IgG-MMAE, and 19G4-MMAE solutions were added to cells for 72 h incubation at 37 °C. Cell viability were evaluated in triplicate by MTT assay. The IC50 was determined using Graphpad Prism version 9 (GraphPad Software, Inc.).
Click to Show/Hide
|
||||
| In Vitro Model | Nasopharyngeal carcinoma | NPC/HK1 cells | CVCL_7084 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
235.4 nM
|
Positive SLCA2 expression (SLCA2+++/++) | ||
| Method Description |
The MTT assay was performed to determin the in vitro efficacy of the 19G4-MMAE ADC. Cells were seeded in 96-well plates at a density of 5000 cells/well for SCC15, NPC/HK1, FADU, C666-1 at 37 °C and 5% CO2 overnight. Dilutions of PBS, 19G4, IgG-MMAE, and 19G4-MMAE solutions were added to cells for 72 h incubation at 37 °C. Cell viability were evaluated in triplicate by MTT assay. The IC50 was determined using Graphpad Prism version 9 (GraphPad Software, Inc.).
Click to Show/Hide
|
||||
| In Vitro Model | Hypopharyngeal squamous cell carcinoma | FaDu cells | CVCL_1218 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
344.4 nM
|
Negative SLCA2 expression (SLCA2-) | ||
| Method Description |
The MTT assay was performed to determin the in vitro efficacy of the 19G4-MMAE ADC. Cells were seeded in 96-well plates at a density of 5000 cells/well for SCC15, NPC/HK1, FADU, C666-1 at 37 °C and 5% CO2 overnight. Dilutions of PBS, 19G4, IgG-MMAE, and 19G4-MMAE solutions were added to cells for 72 h incubation at 37 °C. Cell viability were evaluated in triplicate by MTT assay. The IC50 was determined using Graphpad Prism version 9 (GraphPad Software, Inc.).
Click to Show/Hide
|
||||
| In Vitro Model | Nasopharyngeal carcinoma | C666-1 cells | CVCL_7949 | ||
References